INSERM CIC-P0005 Pharmaco-épidémiologie, INSERM U657, Service de Pharmacologie, Université Bordeaux Segalen, Bâtiment Le Tondu, Case 41, 146, Rue Léo Saignat, 33076 Bordeaux Cedex, France.
Drug Saf. 2013 Feb;36(2):135-44. doi: 10.1007/s40264-012-0013-7.
Most NSAIDs are thought to be able to cause hepatic injury and acute liver failure (ALF), but the event rates of those leading to transplantation (ALFT) remain uncertain.
The aim of the study was to estimate population event rates for NSAID-associated ALFT METHODS: This was a case-population study of ALFT in 57 eligible liver transplant centres in seven countries (France, Greece, Ireland, Italy, The Netherlands, Portugal and the UK). Cases were all adults registered from 2005 to 2007 for a liver transplant following ALFT without identified clinical aetiology, exposed to an NSAID or paracetamol (acetaminophen) within 30 days before the onset of clinical symptoms. NSAID and paracetamol population exposures were assessed using national sales data from Intercontinental Marketing Services (IMS). Risk was estimated as the rate of ALFT per million treatment-years (MTY).
In the 52 participating centres, 9479 patients were registered for transplantation, with 600 for ALFT, 301 of whom, without clinical aetiology, had been exposed to a drug within 30 days. Of these 301 patients, 40 had been exposed to an NSAID and 192 to paracetamol (81 of whom were without overdose). Event rates per MTY were 1.59 (95 % CI 1.1-2.2) for all NSAIDs pooled, 2.3 (95 % CI 1.2-3.9) for ibuprofen, 1.9 (95 % CI 0.8-3.7) for nimesulide, 1.6 (95 % CI 0.6-3.4) for diclofenac and 1.6 (95 % CI 0.3-4.5) for ketoprofen. For paracetamol, the event rate was 3.3 per MTY (95 % CI 2.6-4.1) without overdoses and 7.8 (95 % CI 6.8-9.0) including overdoses.
ALF leading to registration for transplantation after exposure to an NSAID was rare, with no major difference between NSAID. Non-overdose paracetamol-exposed liver failure was twice more common than NSAID-exposed liver failure.
大多数非甾体抗炎药(NSAIDs)被认为能够导致肝损伤和急性肝衰竭(ALF),但导致肝移植(ALFT)的事件发生率仍不确定。
本研究旨在估计 NSAID 相关 ALFT 的人群事件发生率。
这是一项在七个国家(法国、希腊、爱尔兰、意大利、荷兰、葡萄牙和英国)的 57 家合格肝移植中心进行的 ALFT 病例-人群研究。病例均为 2005 年至 2007 年期间因 ALFT 而登记接受肝移植的成年人,无明确临床病因,在临床症状出现前 30 天内接触过 NSAID 或对乙酰氨基酚(扑热息痛)。使用 Intercontinental Marketing Services(IMS)的国家销售数据评估 NSAID 和对乙酰氨基酚的人群暴露情况。风险估计为每百万治疗年(MTY)的 ALFT 发生率。
在 52 家参与中心中,有 9479 名患者登记接受移植,其中 600 名因 ALFT 接受治疗,其中 301 名无临床病因,在 30 天内接触过药物。在这 301 名患者中,40 名接触过 NSAID,192 名接触过对乙酰氨基酚(其中 81 名无过量)。所有 NSAID 汇总的 MTY 发生率为 1.59(95%CI 1.1-2.2),布洛芬为 2.3(95%CI 1.2-3.9),尼美舒利为 1.9(95%CI 0.8-3.7),双氯芬酸为 1.6(95%CI 0.6-3.4),酮洛芬为 1.6(95%CI 0.3-4.5)。对于对乙酰氨基酚,无过量时 MTY 发生率为 3.3(95%CI 2.6-4.1),包括过量时为 7.8(95%CI 6.8-9.0)。
接触 NSAID 后导致登记接受肝移植的 ALF 很少见,NSAID 之间没有明显差异。非过量接触对乙酰氨基酚导致的肝衰竭比 NSAID 导致的肝衰竭常见两倍。